US 12,201,419 B2
Infrared spectroscopic devices and methods of use for transdermal patient assessment
Jitto Titus, Acworth, GA (US); and Atandra Burman, Bermuda Dunes, CA (US)
Assigned to RCE Technologies, Inc, Carlsbad, CA (US)
Filed by RCE Technologies, Inc., Bermuda Dunes, CA (US)
Filed on Nov. 30, 2021, as Appl. No. 17/537,932.
Application 17/537,932 is a continuation in part of application No. 17/333,118, filed on May 28, 2021.
Claims priority of provisional application 63/148,384, filed on Feb. 11, 2021.
Claims priority of provisional application 63/032,904, filed on Jun. 1, 2020.
Prior Publication US 2022/0079473 A1, Mar. 17, 2022
Int. Cl. A61B 5/1455 (2006.01); A61B 5/00 (2006.01); A61B 5/026 (2006.01); A61B 5/145 (2006.01)
CPC A61B 5/1455 (2013.01) [A61B 5/0075 (2013.01); A61B 5/0261 (2013.01); A61B 5/14546 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A system comprising:
a transdermal optical monitoring device configured to perform Attenuated Total Reflectance to generate an evanescent wave to interrogate an epidermis of a subject;
an analysis system in communication with the transdermal optical monitoring device, the analysis system configured to perform a method comprising:
receiving, from the transdermal optical monitoring device, a predetermined number of optical scans, each of the optical scans comprising data indicative of absorption of light at a range of 6.4-6.9 micrometers and a range of 8-14 micrometers by the subject, the absorption caused in response to the transdermal optical monitoring device transmitting light pulses towards the subject in a transdermal manner;
establishing a baseline measurement for an inframarker based on the data from the predetermined number of optical scans, the inframarker being indicative of a single one or a combination of biomarkers representing a physiological state of the subject, including myocardial injury and/or myocardial stress;
receiving, from the transdermal optical monitoring device, a first optical scan comprising a first measurement of the inframarker, the first optical scan being different from the predetermined number of optical scans;
calculating a difference between the first measurement of the inframarker and the baseline measurement of the inframarker;
in response to the difference exceeding a predetermined delta, detecting a change in the physiological state of the subject; and
adjusting a frequency of capturing the data from the transdermal optical monitoring device based on a magnitude of the predetermined delta, the frequency being lower when the predetermined delta is within a first predefined range, the frequency being higher when the predetermined delta is within a second predefined range.